Skip to main content
Top
Published in: Familial Cancer 4/2009

01-12-2009

Mutation screening of VHL gene in a family with malignant bilateral pheochromocytoma: from isolated familial pheochromocytoma to von Hippel-Lindau disease

Authors: Shirin Hasani-Ranjbar, Mahsa M. Amoli, Azadeh Ebrahim-Habibi, Vahid Haghpanah, Maryam Hejazi, Akbar Soltani, Bagher Larijani

Published in: Familial Cancer | Issue 4/2009

Login to get access

Abstract

von Hippel-Lindau (vHL) disease is an inherited, autosomal dominant syndrome manifested by a variety of benign and malignant tumors. More than 300 germline VHL mutations have been identified that are involved in VHL disease. A large family (four generations) was evaluated. In this paper we report the presence of a single nucleotide mutation in exon 3 of VHL gene c499 C>T causing substitution of Arginine by Tryptophan at position 167 (R 167 W). It was detected in a family with bilateral malignant pheochromocytoma who has been followed for at least 9 years as RET negative isolated familial pheochromocytoma, finally diagnosed as von Hipple-Lindau disease according to retinal angioma and VHL gene mutation. VHL type 2 presenting with both pheochromocytoma and retinal angioma in this family found to be associated with the new missense mutation (c499 C>T) of VHL gene.
Literature
1.
go back to reference Stein PP, Black HR (1991) A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution’s experience. Medicine (Baltimore) 70:46–66 Stein PP, Black HR (1991) A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution’s experience. Medicine (Baltimore) 70:46–66
2.
go back to reference Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS (2001) Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315–329PubMed Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS (2001) Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315–329PubMed
3.
go back to reference Neumann HP, Bausch B, McWhinney SR et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459–1466CrossRefPubMed Neumann HP, Bausch B, McWhinney SR et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459–1466CrossRefPubMed
4.
go back to reference Young WF Jr, Abboud AL (2006) Editorial: Paraganglioma—all in the family. J Clin Endocrinol Metab 91:790–792CrossRefPubMed Young WF Jr, Abboud AL (2006) Editorial: Paraganglioma—all in the family. J Clin Endocrinol Metab 91:790–792CrossRefPubMed
5.
go back to reference Neumann HP, Pawlu C, Peczkowska M et al (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943–951CrossRefPubMed Neumann HP, Pawlu C, Peczkowska M et al (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943–951CrossRefPubMed
6.
go back to reference Erlic Z, Neumann HP (2009) Familial pheochromocytoma. Hormones (Athens) 8:29–38 Erlic Z, Neumann HP (2009) Familial pheochromocytoma. Hormones (Athens) 8:29–38
7.
go back to reference Maher ER, Yates JR, Harries R et al (1990) Clinical features and natural history of von Hippel-Lindau disease. Q J Med 77:1151–1163PubMed Maher ER, Yates JR, Harries R et al (1990) Clinical features and natural history of von Hippel-Lindau disease. Q J Med 77:1151–1163PubMed
8.
9.
go back to reference Maher ER, Kaelin WG Jr (1997) von Hippel-Lindau disease. Medicine (Baltimore) 76:381–391CrossRef Maher ER, Kaelin WG Jr (1997) von Hippel-Lindau disease. Medicine (Baltimore) 76:381–391CrossRef
10.
go back to reference Patocs A, Gergics P, Balogh K et al (2008) Ser80Ile mutation and a concurrent Pro25Leu variant of the VHL gene in an extended Hungarian von Hippel-Lindau family. BMC Med Genet 9:29CrossRefPubMed Patocs A, Gergics P, Balogh K et al (2008) Ser80Ile mutation and a concurrent Pro25Leu variant of the VHL gene in an extended Hungarian von Hippel-Lindau family. BMC Med Genet 9:29CrossRefPubMed
11.
go back to reference Zbar B, Kishida T, Chen F et al (1996) Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8:348–357CrossRefPubMed Zbar B, Kishida T, Chen F et al (1996) Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8:348–357CrossRefPubMed
12.
go back to reference Schreinemakers JM, Zonnenberg BA, Höppener JW, Hes FJ, Rinkes IH, Lips CJ (2007) A patient with bilateral pheochromocytoma as part of a Von Hippel-Lindau (VHL) syndrome type 2C. World J Surg Oncol 5:112CrossRefPubMed Schreinemakers JM, Zonnenberg BA, Höppener JW, Hes FJ, Rinkes IH, Lips CJ (2007) A patient with bilateral pheochromocytoma as part of a Von Hippel-Lindau (VHL) syndrome type 2C. World J Surg Oncol 5:112CrossRefPubMed
13.
go back to reference Latif F, Tory K, Gnarra J, Yao M et al (1993) Identification of the von Hippel-Lindau Disease tumor suppressor gene. Science 260:1317–1320CrossRefPubMed Latif F, Tory K, Gnarra J, Yao M et al (1993) Identification of the von Hippel-Lindau Disease tumor suppressor gene. Science 260:1317–1320CrossRefPubMed
14.
15.
go back to reference Cruz JB, Fernandes LP, Clara SA et al (2007) Molecular analysis of the Von Hippel-Lindau (VHL) gene in a family with non-syndromic pheochromocytoma: the importance of genetic testing. Arq Bras Endocrinol Metabol 51:1463–1467PubMed Cruz JB, Fernandes LP, Clara SA et al (2007) Molecular analysis of the Von Hippel-Lindau (VHL) gene in a family with non-syndromic pheochromocytoma: the importance of genetic testing. Arq Bras Endocrinol Metabol 51:1463–1467PubMed
16.
go back to reference Alvandi E, Pedram M, Soroush AR, Naier BN, Akrami SM (2007) Detection of RET Proto-oncogene Cys634Arg mutation, the cause of medullary thyroid carcinoma, in an Iranian child. Iran J Pediatr 17(Suppl 2):301–305 Alvandi E, Pedram M, Soroush AR, Naier BN, Akrami SM (2007) Detection of RET Proto-oncogene Cys634Arg mutation, the cause of medullary thyroid carcinoma, in an Iranian child. Iran J Pediatr 17(Suppl 2):301–305
17.
go back to reference Lindahl E, Azuara C, Koehl P, Delarue M (2006) NOMAD-Ref: visualization, deformation and refinement of macromolecular structures based on all-atom normal mode analysis. Nucleic Acids Res 34:W52–W56CrossRefPubMed Lindahl E, Azuara C, Koehl P, Delarue M (2006) NOMAD-Ref: visualization, deformation and refinement of macromolecular structures based on all-atom normal mode analysis. Nucleic Acids Res 34:W52–W56CrossRefPubMed
18.
19.
go back to reference Duan DR, Pause A, Burgess WH et al (1995) Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269:1402–1406CrossRefPubMed Duan DR, Pause A, Burgess WH et al (1995) Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269:1402–1406CrossRefPubMed
20.
go back to reference Kishida T, Stackhouse TM, Chen F, Lerman MI, Zbar B (1995) Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res 55:4544–4548PubMed Kishida T, Stackhouse TM, Chen F, Lerman MI, Zbar B (1995) Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res 55:4544–4548PubMed
21.
go back to reference Stebbins CE, Kaelin WG, Pavlevitch NP (1999) Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284:455–461CrossRefPubMed Stebbins CE, Kaelin WG, Pavlevitch NP (1999) Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284:455–461CrossRefPubMed
22.
go back to reference Opocher G, Schiavi F, Iacobone M et al (2006) Familial nonsyndromic pheochromocytoma. Ann N Y Acad Sci 1073:149–155CrossRefPubMed Opocher G, Schiavi F, Iacobone M et al (2006) Familial nonsyndromic pheochromocytoma. Ann N Y Acad Sci 1073:149–155CrossRefPubMed
23.
go back to reference Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher ER, Plouin PF, European Network for the Study of Adrenal Tumours (ENS@T) Pheochromocytoma Working Group (2006) Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) 65:699–705CrossRef Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher ER, Plouin PF, European Network for the Study of Adrenal Tumours (ENS@T) Pheochromocytoma Working Group (2006) Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) 65:699–705CrossRef
24.
go back to reference Kaelin WG Jr (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673–682CrossRefPubMed Kaelin WG Jr (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673–682CrossRefPubMed
25.
go back to reference Ritter MM, Frilling A, Crossey PA et al (1996) Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease. J Clin Endocrinol Metab 81:1035–1037CrossRefPubMed Ritter MM, Frilling A, Crossey PA et al (1996) Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease. J Clin Endocrinol Metab 81:1035–1037CrossRefPubMed
26.
go back to reference Tong AL, Zeng ZP, Li HZ et al (2006) von Hippel-Lindau gene mutation in non-syndromic familial pheochromocytomas. Ann N Y Acad Sci 1073:203–207CrossRefPubMed Tong AL, Zeng ZP, Li HZ et al (2006) von Hippel-Lindau gene mutation in non-syndromic familial pheochromocytomas. Ann N Y Acad Sci 1073:203–207CrossRefPubMed
27.
go back to reference Eng C, Crossey PA, Mulligan LM et al (1995) Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 32:934–937CrossRefPubMed Eng C, Crossey PA, Mulligan LM et al (1995) Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 32:934–937CrossRefPubMed
28.
go back to reference Stolle C, Glenn G, Zbar B et al (1998) Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12:417–423CrossRefPubMed Stolle C, Glenn G, Zbar B et al (1998) Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12:417–423CrossRefPubMed
29.
go back to reference Korpershoek E, Petri BJ, van Nederveen FH et al (2007) Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma. Endocr Relat Cancer 14:453–462CrossRefPubMed Korpershoek E, Petri BJ, van Nederveen FH et al (2007) Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma. Endocr Relat Cancer 14:453–462CrossRefPubMed
30.
go back to reference Dollfus H, Massin P, Taupin P et al (2002) Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophthalmol Vis Sci 43:3067–3074PubMed Dollfus H, Massin P, Taupin P et al (2002) Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophthalmol Vis Sci 43:3067–3074PubMed
31.
go back to reference Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9:677–684CrossRefPubMed Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9:677–684CrossRefPubMed
Metadata
Title
Mutation screening of VHL gene in a family with malignant bilateral pheochromocytoma: from isolated familial pheochromocytoma to von Hippel-Lindau disease
Authors
Shirin Hasani-Ranjbar
Mahsa M. Amoli
Azadeh Ebrahim-Habibi
Vahid Haghpanah
Maryam Hejazi
Akbar Soltani
Bagher Larijani
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2009
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9266-4

Other articles of this Issue 4/2009

Familial Cancer 4/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine